Retrophin Initiates Pivotal Phase 3 Clinical Trial of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis

SAN DIEGO, April 03, 2018 (GLOBE NEWSWIRE) — Retrophin, Inc. (NASDAQ:RTRX) today announced that the first patient has been enrolled in the DUPLEX Study, a global, pivotal Phase 3 clinical trial evaluating the long-term nephroprotective potential of sparsentan for the treatment of focal segmental